Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B venture round brings in $7.9mm for Clearside Biomedical, which closes financing at $16mm

Executive Summary

Clearside Biomedical Inc. (ophthalmic drug delivery that does not require surgery) has raised $7.9mm through its Series B venture round. There were 13 investors, including new backer Mountain Group Capital and current shareholders Hatteras Venture Partners, Georgia Research Alliance Venture Fund, and Kenan Flagler Business School Private Equity Fund. Santen Pharmaceutical Co. Ltd. also participated as part of its concurrently announced research alliance for posterior ocular disease therapeutics.
Deal Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies